Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

Share this content:
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

Sponsors and collaborators
Massachusetts General Hospital
Pfizer
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute

Contact
Beverly Spicer, RN
Phone: 617-726-8235
E-mail: bspicer@partners.org

ClinicalTrials.gov Identifier
NCT00556049
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters